Pan Tumor Rollover Study
CancerMain Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
null
Conditions de participation
-
Sexe:
ALL -
Âges admissibles:
18 and up
Critères de participation
Inclusion Criteria:
* Signed Written Informed Consent.
* Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study.
* On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study.
* WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF.
Exclusion Criteria:
* Participant is not eligible for study treatment per the Parent Study eligibility criteria.
* Participants not receiving clinical benefit as assessed by the Investigator.
* Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant.
* Other protocol-defined Inclusion/Exclusion Criteria apply
Lieu de l'étude
Local Institution
Local InstitutionVancouver, British Columbia
Canada
Contactez l'équipe d'étude
Local Institution - 0040
Local Institution - 0040Montreal, Quebec
Canada
Contactez l'équipe d'étude
Local Institution - 0111
Local Institution - 0111Edmonton, Alberta
Canada
Contactez l'équipe d'étude
Site 0111
Princess Margaret Cancer Centre
Princess Margaret Cancer CentreToronto, Ontario
Canada
Contactez l'équipe d'étude
Marcus Butler, Site 0280
4169464628Local Institution - 0308
Local Institution - 0308Montreal, Quebec
Canada
Contactez l'équipe d'étude
Site 0308
Local Institution
Local InstitutionHalifax, Nova Scotia
Canada
Contactez l'équipe d'étude
Local Institution - 0168
Local Institution - 0168Oshawa, Ontario
Canada
Contactez l'équipe d'étude
- Étude parrainée par
- Bristol-Myers Squibb
- Participants recherchés
- Plus d'informations
- ID de l'étude:
NCT03899155